|
Post by kimi on Jan 19, 2018 7:01:51 GMT -5
|
|
|
Post by akemp3000 on Jan 19, 2018 7:09:57 GMT -5
Excellent. Good to see Deerfield is continuing to work with Mannkind and is obviously expecting the company to grow. Thanks Kimi.
|
|
|
Post by golfeveryday on Jan 19, 2018 7:14:56 GMT -5
Excellent. Good to see Deerfield is continuing to work with Mannkind and is obviously expecting the company to grow. Thanks Kimi. they converted half of the $10M to shares which is more positive than usual. The rest was mnkd giving shares as partial payment, extending the remaining small payment until May 2018, and renegotiating a conversion price on another note to $2.75. Just a quick read early in the morn. Not sure if that is 100% accurate. Seems DF is slowly loading the boat now on the Long side.
|
|
|
Post by silentknight on Jan 19, 2018 7:19:15 GMT -5
This is why MNKD needed an updated share count. Looks like they're going to be paying all their debt by issuing new shares.
I think it's the only option they have, since they obviously don't have cash to pay the debt, but I don't expect the market to react favorably to the news. Paying your debts by diluting your shareholders isn't typically a strategy that the Street looks upon favorably.
Scripts need to pick up in a big way. That will likely be the only thing that has any positive impact.
|
|
|
Post by silentknight on Jan 19, 2018 7:20:59 GMT -5
To summarize, of the $10M owes to Deerfield on Jan 15: we paid them $5.6M, converted $3.15M to 1.27M shares, and deferred payment of the remaining $1.25M to May 6, 2018. The way I read it, through Jan 15,2018 the approx. $5.6 million was converted to common shares, i.e. new shares issued. We then issued more shares for another approx. $3.1 million yesterday. We didn't pay Deerfield anything.
|
|
|
SEC
Jan 19, 2018 7:21:47 GMT -5
via mobile
peppy likes this
Post by tarheelblue004 on Jan 19, 2018 7:21:47 GMT -5
To summarize, of the $10M owes to Deerfield on Jan 15: we paid them $5.6M, converted $3.15M to 1.27M shares, and deferred payment of the remaining $1.25M to May 6, 2018. The way I read it, approx. $5.6 million was converted to common shares, i.e. new shares issued. We didn't pay Deerfield anything. Agreed. Realized my error and deleted the post.
|
|
|
Post by hellodolly on Jan 19, 2018 7:28:40 GMT -5
This is why MNKD needed an updated share count. Looks like they're going to be paying all their debt by issuing new shares. I think it's the only option they have, since they obviously don't have cash to pay the debt, but I don't expect the market to react favorably to the news. Paying your debts by diluting your shareholders isn't typically a strategy that the Street looks upon favorably. Scripts need to pick up in a big way. That will likely be the only thing that has any positive impact. "I think it's the only option they have, since they obviously don't have cash to pay the debt, but I don't expect the market to react favorably to the news. Paying your debts by diluting your shareholders isn't typically a strategy that the Street looks upon favorably."
#1- Um, you're forgetting that MNKD could still generate other sources of revenue to pay back their debt. Partner buy-ins, for example. #2- This is not a long term solution but a quick fix. It's not a solid corporate long term strategy in any playbook, it comes from the short list. #3- While the market may react unfavorably, that too is only temporary. #4- Scripts are not the ONLY thing that can have a positive impact. Announcements of better insurance coverage, partnerships, cash infused buy-ins, positive news from ADA, etc are also additional sources that can have a positive impact.
Just my humble thoughts and opinions. - Best regards.
|
|
|
Post by peppy on Jan 19, 2018 7:33:39 GMT -5
Deerfield keeps loading.... paying slightly higher prices each round, averaging up.
MNKD keeps hiring.
|
|
|
Post by mnholdem on Jan 19, 2018 7:34:33 GMT -5
New payment schedule (from 1/19/18 SEC filing):
$5 million due May-2018 and $25 million due by the end of July-2018 ($10M must be applied to the Dec-2019 Tranche B and Tranche 4) before being applied to the Tranche 4 in July-2018).
Way to go, Steve! You da' Man!
|
|
|
Post by tarheelblue004 on Jan 19, 2018 8:02:12 GMT -5
This is why MNKD needed an updated share count. Looks like they're going to be paying all their debt by issuing new shares. I think it's the only option they have, since they obviously don't have cash to pay the debt, but I don't expect the market to react favorably to the news. Paying your debts by diluting your shareholders isn't typically a strategy that the Street looks upon favorably. Scripts need to pick up in a big way. That will likely be the only thing that has any positive impact. I expect Wall Street to shrug it off. ~2.5% dilution for a small biotech with large potential.
|
|
|
Post by silentknight on Jan 19, 2018 8:06:02 GMT -5
This is why MNKD needed an updated share count. Looks like they're going to be paying all their debt by issuing new shares. I think it's the only option they have, since they obviously don't have cash to pay the debt, but I don't expect the market to react favorably to the news. Paying your debts by diluting your shareholders isn't typically a strategy that the Street looks upon favorably. Scripts need to pick up in a big way. That will likely be the only thing that has any positive impact. "I think it's the only option they have, since they obviously don't have cash to pay the debt, but I don't expect the market to react favorably to the news. Paying your debts by diluting your shareholders isn't typically a strategy that the Street looks upon favorably."
#1- Um, you're forgetting that MNKD could still generate other sources of revenue to pay back their debt. Partner buy-ins, for example. #2- This is not a long term solution but a quick fix. It's not a solid corporate long term strategy in any playbook, it comes from the short list. #3- While the market may react unfavorably, that too is only temporary. #4- Scripts are not the ONLY thing that can have a positive impact. Announcements of better insurance coverage, partnerships, cash infused buy-ins, positive news from ADA, etc are also additional sources that can have a positive impact.
Just my humble thoughts and opinions. - Best regards.
I agree that all of those things COULD have an impact, but they haven't to date. MNKD's only substantive partnership since the Sanofi termination was for Brazil, and that didn't provide a single penny in up-front money that would enable MNKD to pay down debt or use for company operations. It's easy to ponder what could have positive impact for the company. The possibilities are limitless. Instead, I prefer to focus on what HAS occurred in the past, and use that as somewhat of an indicator as to what will likely happen in the future. Using that formula, I expect only scripts to have any real impact on the bottom line. Ultimately, it's sales that matter and nothing else.
|
|
|
Post by peppy on Jan 19, 2018 8:13:45 GMT -5
at this moment I prefer to focus on scripts and insurance coverage. Deerfield buying in, there is a plan. So it's insurance and the big nut to crack is united health. once the physicians can write for Afrezza with out calls from the pharmacy purchasing managers that they are writing out of Prepared, it will be easier for them to write for Afrezza. The stat study release in July.
|
|
|
Post by hellodolly on Jan 19, 2018 9:06:58 GMT -5
"I think it's the only option they have, since they obviously don't have cash to pay the debt, but I don't expect the market to react favorably to the news. Paying your debts by diluting your shareholders isn't typically a strategy that the Street looks upon favorably."
#1- Um, you're forgetting that MNKD could still generate other sources of revenue to pay back their debt. Partner buy-ins, for example. #2- This is not a long term solution but a quick fix. It's not a solid corporate long term strategy in any playbook, it comes from the short list. #3- While the market may react unfavorably, that too is only temporary. #4- Scripts are not the ONLY thing that can have a positive impact. Announcements of better insurance coverage, partnerships, cash infused buy-ins, positive news from ADA, etc are also additional sources that can have a positive impact.
Just my humble thoughts and opinions. - Best regards.
I agree that all of those things COULD have an impact, but they haven't to date. MNKD's only substantive partnership since the Sanofi termination was for Brazil, and that didn't provide a single penny in up-front money that would enable MNKD to pay down debt or use for company operations. It's easy to ponder what could have positive impact for the company. The possibilities are limitless. Instead, I prefer to focus on what HAS occurred in the past, and use that as somewhat of an indicator as to what will likely happen in the future. Using that formula, I expect only scripts to have any real impact on the bottom line. Ultimately, it's sales that matter and nothing else. I'm careful with my words, "COULD" doesn't pigeon hole me or put me in a trick bag. Regardless, your points are worth noting yet, I was pointing out that based on past performance being a good indicator of the future, our SP has turned the corner now for several months. Even without the expanded list of potential partners who could inject cash into MNKD, or any announcements, one has to also take into consideration that the decisions that are being made and those that have been made by MNKD IS having a longer term positive reflection on the SP.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 19, 2018 9:16:56 GMT -5
"I think it's the only option they have, since they obviously don't have cash to pay the debt, but I don't expect the market to react favorably to the news. Paying your debts by diluting your shareholders isn't typically a strategy that the Street looks upon favorably."
#1- Um, you're forgetting that MNKD could still generate other sources of revenue to pay back their debt. Partner buy-ins, for example. #2- This is not a long term solution but a quick fix. It's not a solid corporate long term strategy in any playbook, it comes from the short list. #3- While the market may react unfavorably, that too is only temporary. #4- Scripts are not the ONLY thing that can have a positive impact. Announcements of better insurance coverage, partnerships, cash infused buy-ins, positive news from ADA, etc are also additional sources that can have a positive impact.
Just my humble thoughts and opinions. - Best regards.
I agree that all of those things COULD have an impact, but they haven't to date. MNKD's only substantive partnership since the Sanofi termination was for Brazil, and that didn't provide a single penny in up-front money that would enable MNKD to pay down debt or use for company operations. It's easy to ponder what could have positive impact for the company. The possibilities are limitless. Instead, I prefer to focus on what HAS occurred in the past, and use that as somewhat of an indicator as to what will likely happen in the future. Using that formula, I expect only scripts to have any real impact on the bottom line. Ultimately, it's sales that matter and nothing else. Mannkind has one choice to increase share price, move the metal. Everything else is noise. Better formulary helps, better label helps but it comes down to one thing and only one thing, sales.
|
|
|
Post by mnholdem on Jan 19, 2018 10:03:18 GMT -5
"I think it's the only option they have, since they obviously don't have cash to pay the debt, but I don't expect the market to react favorably to the news. Paying your debts by diluting your shareholders isn't typically a strategy that the Street looks upon favorably."
[Clipped]
Just my humble thoughts and opinions. - Best regards.
I agree that all of those things COULD have an impact, but they haven't to date. MNKD's only substantive partnership since the Sanofi termination was for Brazil, and that didn't provide a single penny in up-front money that would enable MNKD to pay down debt or use for company operations. It's easy to ponder what could have positive impact for the company. The possibilities are limitless. Instead, I prefer to focus on what HAS occurred in the past, and use that as somewhat of an indicator as to what will likely happen in the future. Using that formula, I expect only scripts to have any real impact on the bottom line. Ultimately, it's sales that matter and nothing else. While what you say is true that the MannKind-Biomm deal (for marketing Afrezza in Brazil) did not bring in upfront $ that can be used for debt obligations or operations, it's also a fact that Biomm has agreed to pick up all the costs associated with registering Afrezza with ANVISA in Brazil. I'm not certain what the cost of registration is, but at least MannKind doesn't have to pay anything to get their product into that country.
|
|